Objective: Nemaline myopathy (NM) is one of the most common congenital nondystrophic myopathies and is characterized by muscle weakness, often from birth. Mutations in ACTA1 are a frequent cause of NM (ie, NEM3). ACTA1 encodes alpha-actin 1, the main constituent of the sarcomeric thin filament. The mechanisms by which mutations in ACTA1 contribute to muscle weakness in NEM3 are incompletely understood. We hypothesized that sarcomeric dysfunction contributes to muscle weakness in NEM3 patients. Methods: To test this hypothesis, we performed contractility measurements in individual muscle fibers and myofibrils obtained from muscle biopsies of 14 NEM3 patients with different ACTA1 mutations. To identify the structural basis for impaired contractility, low angle X-ray diffraction and stimulated emission-depletion microscopy were applied. Results: Our findings reveal that muscle fibers of NEM3 patients display a reduced maximal force-generating capacity, which is caused by dysfunctional sarcomere contractility in the majority of patients, as revealed by contractility measurements in myofibrils. Low angle X-ray diffraction and stimulated emission-depletion microscopy indicate that dysfunctional sarcomere contractility in NEM3 patients involves a lower number of myosin heads binding to actin during muscle activation. This lower number is not the result of reduced thin filament length. Interestingly, the calcium sensitivity of force is unaffected in some patients, but decreased in others. Interpretation: Dysfunctional sarcomere contractility is an important contributor to muscle weakness in the majority of NEM3 patients. This information is crucial for patient stratification in future clinical trials.
(42kDa), which forms the backbone of muscle thin filaments. The thin filament is a sarcomeric microstructure that is essential for proper muscle contraction; binding of myosin to actin is the molecular basis of force generation by skeletal muscle.
The mechanisms by which mutations in ACTA1 contribute to contractile weakness in NEM3 patients are incompletely understood. Recent work on muscle biopsies from NEM3 patients indicated that these mechanisms include, depending on the type of mutation, a reduction in length of the thin filament 19 and structural damage to myofibrils. 20, 21 It is unknown whether mutations in ACTA1 affect the contractility of structurally intact sarcomeres. Knowledge on sarcomere contractility in NEM3 patients has therapeutic implications; targeting muscle with structural damage in sarcomeres is cumbersome. Conversely, sarcomeres that are structurally intact, but dysfunctional, can be targeted with small molecules such as troponin activators. [22] [23] [24] Studies on animal models of NEM3 suggest that sarcomere dysfunction contributes to contractile weakness, [25] [26] [27] [28] [29] [30] but whether these findings translate to patients remains unknown. Considering the role of actin in sarcomeric contractility, we hypothesized that sarcomeric dysfunction contributes to contractile weakness in NEM3 patients.
To test this hypothesis, we performed contractility measurements in individual muscle fibers and myofibrils obtained from muscle biopsies from 14 patients with NEM3. To identify the structural basis for impaired contractility in NEM3 patients, low angle X-ray diffraction and stimulated emission-depletion microscopy were applied. Our findings reveal that sarcomeric dysfunction is an important contributor to contractile weakness in the majority of NEM3 patients.
Materials and Methods

Muscle Biopsies
Biopsies were obtained from the Boston Children's Hospital (NEM3-P1-NEM3-P4), Children's Hospital at Westmead (NEM3-P5-NEM3-P10 and healthy controls [CTRL] 1-4), Myology Institute in Paris (NEM3-P11-NEM3-P14), and Radboud University Medical Center in Nijmegen (CTRL 5-7). Table 1 provides clinical and genetic data for the subjects. From all participants, written informed consent was obtained for genetic testing, biobanking, and analysis of muscle biopsies. Biopsies NEM3-P1 to NEM3-P14 were all from genetically confirmed NEM3 patients with clinicopathological diagnoses of NM. CTRL 1 to 7 are control subjects with no medical history. All biopsies were stored frozen and unfixed at 280 8C until use.
Muscle Fiber Contractility
For contractile experiments, we isolated single individual fibers or small fiber bundles from muscle biopsies before permeabilization, as described previously. 31 Fiber bundles (cross-sectional area 5 0.07mm 2 , in the case of atrophic fibers of patients) and single muscle fibers (control subjects and mildly affected patients) were attached to aluminum clips and mounted between a force transducer (model 403A; Aurora Scientific, Aurora, Ontario, Canada) and a length controller (model 315-CI, Aurora Scientific). We used a setup (model 802D, Aurora Scientific) mounted on top of an inverted microscope (Axio Observer A1; Zeiss, Thornwood, NY). Sarcomere length was set using a fast Fourier transform from a region of interest in the real-time camera image and ASI 900B software (Aurora Scientific).
Experiments were performed at a sarcomere length of 2.5 lm, a length at which muscle fibers develop maximal force. The width and the depth of the fibers were measured at 3 points along the fiber with a 340 objective, and the crosssectional area (CSA) was calculated assuming an elliptical cross section. The temperature was kept constant at 20 8C using a TEC Controller (ASI 825A, Aurora Scientific 14 .5mM creatine phosphate). The preparations were activated at pCa 4.5 to obtain maximal Ca 21 -activated force. Maximal active tension was obtained by dividing the force generated at pCa 4.5 by CSA. We studied 6 to 19 fibers or fiber bundles per biopsy.
Preparations were sequentially transferred from relaxing solution to preactivating solution and finally activated with solutions with a pCa ranging from 7.0 to 4.5, obtained by appropriate mixing of the relaxing and activating solution. The force-pCa relation obtained was fitted with a Hill equation, providing pCa 50 (pCa giving 50% of maximal active tension) and the Hill coefficient, n H , an index of myofilament cooperativity. During measurements at pCa 4.5, the rate of force redevelopment (k tr ) was measured when a steady force was reached by performing a quick release of 30% of the initial length, which reduced tension to zero. This was followed by a period of unloaded shortening lasting 30 milliseconds. Thereafter, the remaining bound cross-bridges were mechanically detached by rapidly (1 millisecond) restretching the preparation back to its original length, after which force redeveloped. Directly after the k tr protocol, the active stiffness, defined as the relative proportion of attached and nonattached cross-bridges within an actively contracting fiber, was determined from the change in force upon small amplitude length perturbations (0.3, 0.6, and 0.9% of the fiber length). Stiffness was derived from the slope of the linear regression of the force-length relation. A typical force trace during an experiment is shown in part B of the second figure.
Fiber Typing
Specialized sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis was used to determine the myosin heavy chain isoform composition of the muscle fiber preparations studied in the contractility experiments. In short, muscle fibers were 
Myofibril Contractility
Muscle bundles dissected from patients and healthy individuals were stored in 50%/50% (vol/vol) glycerol/rigor solution (50mM Tris, pH7.0, 100mM NaCl, 2mM KCl, 2mM MgCl2, and 10mM EGTA) containing a cocktail of protease inhibitors (Roche Diagnostics, Indianapolis, IN) at 220 8C for at least 14 days. On the day of experiments, myofibrils were isolated following procedures previously published. In short, a muscle sample was defrosted in rigor solution at 4 8C for 1 hour. A small piece was cut out and homogenized twice for 5 seconds at 12,000 rpm and twice for 3 seconds at 28,000 rpm (Power AHS250 homogenizer, 5mm generator; VWR, Radnor, PA). This procedure resulted in a solution containing single myofibrils that were transferred into an experimental bath containing relaxing solution (pCa 9.0) and maintained at 15 8C. A myofibril was chosen for mechanical measurements based on its striated appearance, and attached between an atomic force cantilever (AFC; ATEC; Nanosensors, Neuchâtel Switzerland; stiffness 5 40.27nN/mm), and a rigid glass microneedle connected to a piezo motor, which allowed computercontrolled length changes to the myofibrils. Throughout the experimental procedures, the myofibrils were imaged with an oil immersion 360 magnification microscope objective. The myofibril length, average sarcomere length, and cross-sectional area were measured at the beginning of the experiments. The myofibrils were set to an average sarcomere length of 2.6 mm before activation.
Myofibril Activation and Mechanical Measurements
Myofibrils were activated in solutions with pCa ranging from 4.5 to 6.5 with a multichannel microperfusion system attached to a double-barreled pipette. [32] [33] [34] When surrounded by a solution containing high Ca 21 concentration, the myofibrils produced force, causing deflection of the AFC. The deflection of the cantilever was recorded using an optical system, 33 and the force (F) was calculated as F 5 k*Dd, where k is the cantilever stiffness and Dd is the cantilever displacement. Forces were normalized to the myofibril cross-sectional area. The force-pCa relation was fitted to a Hill equation, providing pCa 50 (similarly to analyses performed on single fiber force/pCa data) and the Hill coefficient, n H . During maximal activation, myofibrils were subjected to a rapid shortening protocol (amplitude 5 30% of sarcomere length; speed 5 360 mm/s) during which the force declined and rapidly redeveloped to a new steady-state level. We analyzed the k tr after this shortening-stretch procedure, which is a measure of the kinetics of myosin molecules shifting from a weakly bound to a strongly bound (force producing) state. 35 The k tr was analyzed with an exponential equation (a * exp[2k * (t 2 c)] 1 b), where t is time, k is the rate constant for force redevelopment, a is the amplitude of the exponential, and b and c are constants.
Stimulated Emission-Depletion Microscopy
Fibers were dissected and permeabilized as described above. Immunolabeling was performed as described previously. 31 In brief, fibers were stretched, permeabilized, and fixed on a glass slide followed by incubation with Alexa Fluor 488-conjugated Phalloidin (#A12379; Life Technologies, Carlsbad, CA) to stain the thin filament. Preparations were then mounted in Mowiol.
Super-resolution stimulated emission-depletion (STED) imaging was performed on a Leica TCS SP8 STED 3X (Leica Microsystems, Wetzlar, Germany) using an oil immersion objective HCX PL APO STD 3100 (numerical aperture 5 1.4) and gated Hybrid Detectors. Images were deconvolved using Huygens Professional software (Scientific Volume Imaging, Hilversum, the Netherlands). Thin filament length was analyzed by performing line scans along the length of the fiber using ImageJ software (National Institutes of Health, Bethesda, MD). The half of the width at half maximum intensity was used to indicate thin filament length.
X-ray Diffraction Studies
Small-angle X-ray diffraction experiments were performed on the Biophysics Collaborative Access Team beamline 18ID (Argonne National Laboratory, Argonne, IL). Fibers were mounted on a custom X-ray diffraction/muscle mechanics setup designed to fit into the X-ray diffraction instrument. Muscle fibers were attached between a high-speed motor (Model 308B; Cambridge Electronic Design, Cambridge, UK; 1-millisecond 90% step response) and a force transducer (Aurora Scientific Model 402A). Sarcomere length was determined using the firstorder diffraction band from an He-Ne laser. Sarcomere length was set at 2.5 mm. The small-angle diffraction camera length was 3m, and X-ray energy was 12keV. The X-ray exposure times were 1 second with an incident flux of 1 3 10 12 photons/s, and the X-ray diffraction patterns were collected with the use of a Pilatus 3 1M pixel array detector (Dectris, Baden-D€ attwil, Switzerland). Images were taken in 100 frame bursts of 10-millisecond frames separated by 500 milliseconds with the shutter closed to prevent sample heating. In addition, the samples were translated in the beam during the exposures to reduce radiation damage. Separation of the 1,0 equatorial reflections measured from the diffraction pattern were converted to d1,0 lattice spacing via Bragg's law, which can be converted to inter-thick-filament spacing by multiplying d1,0 by 2/ͱ3. Fibers were activated remotely by exchanging the solution with pCa 9.0 for a solution with pCa 4.5.
Statistical Analyses
Data are presented as mean 6 standard error of the mean. Prism 7 (GraphPad, La Jolla, CA) was used to generate descriptive statistics. For statistical analyses, Student t test was applied; p < 0.05 was considered statistically significant. For the analysis of Ca 21 sensitivity of force, we used Mann-Whitney U test to compare each patient to pooled control data; in this case, p < 0.01 was considered significant.
Results
Patients
Muscle biopsies of 14 NEM3 patients and of 7 control subjects were studied. Table 1 shows the age range of the subjects, the disease severity, and mutation location. ; the ribbon structure showing side chains affected by ACTA1 assessed in this study was created with Swiss-FIGURE 1: Molecular model of an actin monomer highlighting the position of mutated residues analyzed in this study. The molecular model of alpha actin was based on a 2.8Å atomic structure of rabbit skeletal muscle actin (RCSB Protein Data Bank 1ATN). 36 The ribbon structure showing side chains affected by ACTA1 assessed in this study was created with Swiss-PDB Viewer v4.1.0. 37 Human alpha skeletal actin is a globular molecule consisting of 2 domains (4 subdomains), which are connected by a "hinge" region (ribbon structure shown in light blue). A cleft is located between the 2 domains containing a divalent cation and adenosine triphosphate (ATP)/adenosine diphosphate (ADP; yellow). Actin polymerizes into 2 twisted strands where each actin molecule interacts with 4 neighboring monomers. The DNase1 binding loop (pale yellow) is involved in actinactin binding by forming a lock-in-key interaction between neighboring actin molecules. Details on further residues involved in actin-actin interactions can be found in Feng and Marston. 53 Actin binds to a number of proteins that are crucial for its function. Important binding partners include nebulin (amino acids involved in binding are 98-103, 127-132, 361-368, 228-238, 4-8, and 350-358, shown in light pink), 53 tropomyosin (Asp27, Arg30, Arg149, Lys328, Lys329, Lys330, Pro335, and Glu336, shown in orange), 56 PdbViewer v4.1.0 37 . All patients harbored a different mutation in ACTA1.
Note that in a previous study 23 we compared the contractility of muscle fibers (ie, maximal tension and the calcium sensitivity of force, the main parameters of the present study as well) isolated from biopsies of pediatric control subjects with those isolated from biopsies of adult control subjects and found that contractility was comparable. Thus, because of ethical considerations, in the present experiments we studied biopsies of adult controls and compared the findings to those of (mainly) pediatric NEM3 patients. Furthermore, due to the limited size of the biopsies not all assays could be performed in the biopsies of all 14 NEM3 patients (per assay the number of studied biopsies is indicated, see below).
Muscle Fiber Contractility
MAXIMAL ACTIVE TENSION. To determine whether mutations in ACTA1 result in abnormal skeletal muscle FIGURE 2: (A) Typical example of a permeabilized muscle fiber preparation of a control subject (left) and of 2 NEM3 patients (middle and right) mounted in the contractility setup. (B) Typical tracing showing the force response to incremental Ca 21 concentrations followed by the measurement of the rate constant of force redevelopment (k tr ) and the active stiffness in a control and an NEM3 patient (P5). (C-F) Maximal active tension (force normalized to cross-sectional area; C), k tr (D), active stiffness (E), and the tension stiffness ratio (F) were significantly lower in NEM3 patients than in control subjects. (G) The force-pCa relationship, giving the average of all controls (n 5 7) and all NEM3 patients (n 5 14), shows no difference in mean calcium sensitivity between the groups. (H) However, analyzing individual patients illustrated that some patients have increased and some have decreased pCa 50 ; "normal range" 5 mean of controls 6 2 standard deviations. (I) The Hill coefficient, n H , was significantly decreased compared to control subjects. Slow-twitch fibers are shown in light shade, fast-twitch fibers in dark shade, bundle of mixed fiber types in intermediate shade (only in NEM3 patients). *p < 0.05. contraction, we determined the maximal force-generating capacity in permeabilized single skeletal muscle fibers and small fiber bundles of all 14 patients (note that, based on previous work, 23 contractile data from single fibers data comparable to data from small fiber bundles). When assessing the morphology of the fibers used for force measurements, we noted that they generally displayed well-preserved sarcomeric structure, but that fiber diameter was markedly reduced (Fig 2A) . Figure 2B shows a typical force trace of a patient's and a control subject's muscle fiber during exposure to incremental Ca 21 concentrations. Note that maximal, absolute force was markedly lower in the fiber of the NEM3 patient compared to that in the control subject's fiber. To determine whether the contractile weakness was caused by atrophy, force was normalized to the cross-sectional area of the fiber (ie, tension). In NEM3 patients, maximal tension of fibers was significantly lower than in fibers of control subjects; tension was reduced by 66%, both fiber types combined (see Fig 2C and Table 2 ). Binning the patients with typical and severe forms of NEM3 and comparing maximal active tension with that in patients Numbers in parentheses represent fiber bundles obtained from biopsy (slow/fast), indicating fiber type composition in the bundles as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. From P14, individual type 1 (left) and type 2 (right) fibers were isolated from the biopsy; both data points are shown in Figure 2C . Data are mean 6 standard error of the mean. with childhood onset/mild forms revealed that patients with mild/childhood onset disease have significantly better contractile function (100.4 6 14.4 vs 55.4 6 11.1mN/mm 2 ; p < 0.01). This suggests that disease severity inversely correlates with fiber contractility. Note that in 9 patients only type 1 fiber bundles were isolated from the biopsy, and in 1 patient both individual type 1 and type 2 fibers were isolated. Thus, as type 1 fibers are predominant in NEM3 muscle, we also performed a subanalysis in which the contractility of type 1 fibers was compared between groups. This analysis showed that the maximal active tension generated by type 1 fibers is reduced by 49% in NEM3 patients, a reduction that is less pronounced than when fiber types are combined. Thus, muscle fibers of NEM3 patients have a reduced force-generating capacity, even after normalizing the force to fiber crosssectional area. These findings suggest that atrophy alone cannot explain the contractile weakness of muscle fibers in NEM3 patients.
To determine the cause of the lower maximal tension of NEM3 fibers, we studied cross-bridge cycling kinetics (see Table 2 ). First, we measured the k tr during maximal activation, which provides information regarding the rate of cross-bridge attachment and detachment. The k tr is significantly lower in fibers of NEM3 patients compared to fibers of control subjects. We also determined the stiffness of muscle fibers during maximal activation, which reflects the number of strongly attached cross-bridges. As shown in Figure 2E , active stiffness was lower in fibers of NEM3 patients compared to fibers of control subjects. Finally, we assessed the force generated per cross-bridge by determining the tension/stiffness ratio (see Fig 2F) . Fibers of NEM3 patients had a significantly lower tension/stiffness ratio than fibers of control subjects.
These results suggest that the reduced tension in NEM3 patients is caused by a reduced number of forcegenerating cross-bridges and by a reduced force generated per cross-bridge.
To study the Ca 21 sensitivity of force generation, fibers were exposed to solutions with incremental Ca 21 concentrations to obtain force-pCa curves, pCa 50 , and Hill coefficient (see Table 2 ). When analyzed as a group, there was no shift in the force-pCa relation of NEM3 fibers compared to fibers of control subjects (see Fig  2G) . However, as shown in Figure 2H , the pCa 50 varied greatly between NEM3 patients, with 4 patients displaying lower calcium sensitivity of force (ie, lower pCa 50 than controls, with 3 of these 4 mutations being located in subdomain 4 of actin; see Fig 1 for details) . Thus, unlike the maximal force-generating capacity, the calcium sensitivity of force of muscle fibers of NEM3 patients is not decreased per se but can also be unaltered, depending on the ACTA1 mutation.
Low Angle X-ray Diffraction
The contractility assays in muscle fibers suggest that in fibers of NEM3 patients a lower number of cross-bridges is attached to actin, and that this contributes to the lower maximal tension. To further explore this, we performed low angle X-ray diffraction on muscle fibers of NEM3 patients. Time-resolved X-ray diffraction provides information on structural changes in muscle fibers during fiber activation with nanometer resolution. Due to the limited size of the biopsy specimens, these experiments were performed in 3 NEM3 patients (P4/P5/P9) and in 3 control subjects. Figure 3A shows a typical equatorial reflection of an NEM3 patient fiber. Analysis of the 1,0 reflection of inactive fibers revealed that thin and thick filament spacing was not different in fibers of NEM3 patients compared to control subjects. Similarly, in inactive fibers the ratio of the 1,1/1,0 intensities, which provides information on the position of the cross-bridges relative to the thin and thick filament, was comparable in NEM3 patients compared to control subjects (see Fig  3B) . Importantly, the expected increase of the 1,1/1,0 ratio intensities during fiber activation was markedly lower in NEM3 patients compared to the control subjects (see Fig 3C) . These findings strengthen the notion that fiber activation results in less actomyosin crossbridge binding in fibers from NEM3 patients compared to fibers from control subjects. Note that the low sample size precluded statistical testing.
Myofibril Contractility
Next, we aimed to confirm that impaired functioning of sarcomeres contributes to fiber weakness in NEM3 patients by performing contractility assays in single myofibrils. Electron microscopy studies on 2 NEM3 patients confirmed that muscle fibers of NEM3 patients contain areas of preserved myofibrillar ultrastructure (Fig 4) . Myofibrils (diameter 5 1-2 mm) were isolated from 8 NEM3 patients and from 6 control subjects. The myofibrils were attached between a rigid glass needle attached to a length motor and an atomic force cantilever used as a force transducer. Representative force traces of a myofibril from an NEM3 patient and a control subject are shown in Figure 4C . Note the lower force generated by the myofibril of the NEM3 patient. Figure 4D shows that the average maximal tension of myofibrils was reduced by 50% in the NEM3 patients, and that the maximal tension of myofibrils of 6 NEM3 patients was lower than that of all control myofibrils. Data on individual subjects are shown in Table 3 . Thus, the mechanical studies on both single fibers and single myofibrils show that cross-bridge cycling kinetics are significantly altered in NEM3 patients.
To rule out that the lower contractile strength of NEM3 patient myofibrils was caused by changes in thin filament length or in thin filament number, we measured thin filament length in myofibrils of 2 NEM3 patients by super-resolution STED microscopy. Analysis of phalloidin line scan intensities revealed that thin filament length in these 2 patients was comparable to thin filament length in control subjects (Fig 5A, right; 1.21 6 0.12 lm in NEM3-P2 and 1.21 6 0.06 lm in NEM3-P5 vs 1.30 6 0.01 lm in CTRL).
Discussion
Over the past decades, >200 mutations in the ACTA1 gene have been identified; however, our understanding of the mechanisms by which these mutations contribute to contractile weakness in NM patients has been limited. Through application of muscle fiber and myofibril contractility assays, low angle X-ray diffraction, and super-resolution microscopy experiments on muscle biopsies from a large cohort of genetically defined NEM3 patients, the current study shows directly that impaired sarcomeric function contributes to muscle weakness in NEM3. Our data show that one mechanism of this impaired function involves reduced numbers of myosin-based cross-bridges binding to actin during muscle activation. Whether sarcomere dysfunction is exclusive to NEM3 patients or also contributes to muscle weakness in patients with other forms of NM is unknown. Studies on fibers of NEM1, NEM2, NEM4, and NEM10 patients suggest the presence of sarcomere dysfunction, 7, 19, [38] [39] [40] [41] [42] [43] but future studies on single myofibrils should provide more conclusive evidence. Sarcomere Dysfunction in NEM3 Patients NEM3 is caused by mutations in ACTA1, which encodes human alpha skeletal actin, a globular molecule (G-actin) consisting of 2 domains (4 subdomains), which are connected by a "hinge" region (ribbon structure shown in light blue in Fig 1) . G-actin polymerizes into 2 twisted strands (F-actin), forming a major structural and functional component of the sarcomeric thin filament. Actin binds to a number of proteins that are crucial for thin filament and sarcomere function, including nebulin, tropomyosin, and myosin. NEM3 is characterized by multiple phenotypes, ranging from late childhood onset with slowly progressive proximal weakness to severe, neonatal onset with facial, respiratory, axial, and limb weakness, resulting in early death. 44 Muscle biopsies normally show numerous rods, but other pathological features have also been described. 45 Data on in vivo muscle function in NEM3 are scarce. Magnetic resonance imaging of muscles of 4 NEM3 patients showed that both lower and upper leg muscles (including the vastus lateralis muscle, from which the majority of the studied biopsies were obtained) had diffuse abnormalities, including fatty replacement of muscle tissue and smaller muscle cross-sectional area. 46, 47 Thus, muscle weakness in NEM3 is at least partly explained by loss of muscle mass. In line with these studies, we observed that isolated muscle fibers of NEM3 patients had smaller cross-sectional area than those of control subjects (see Fig 2A; although note that caution is warranted when comparing permeabilized fibers, as they swell during treatment with triton-X). It is largely unknown whether the remaining muscle mass has normal function or is dysfunctional and contributes to weakness. Recent work from Malfatti et al 21 (and manuscript in preparation) showed that muscle fibers of NEM3 patients contain areas of ultrastructural damage. However, this damage could not fully explain the severe muscle fiber weakness in NEM3 patients. As actin is a central component of the sarcomere, the smallest contractile unit in muscle, defects in this protein might have a direct impact on the contractile function of muscle. It is important to establish whether a contractile defect is present, as this might direct treatment strategies to improve muscle function. 47 To determine sarcomere contractile function, studies in muscles biopsies are indispensable. To date, these studies are scarce; 1 study reported that the p.Phe352Ser mutation in ACTA1 increases contractile function of human muscle fibers. 48 However, this study was based on only 1 patient, precluding firm conclusions. A study from our group on biopsies of 12 NEM3 patients reported that a reduction in length of thin filaments contributes to weakness in some but not all patients. 17 In the present study, we aimed to establish that sarcomere contractile dysfunction contributes to weakness in NEM3 by assessing a large cohort of NEM3 patients. The results show that the maximum force-generating capacity of muscle fibers of NEM3 patients is impaired, on average by 66% (see Fig 2) , the cause of which includes sarcomere dysfunction, as evidenced by (1) the reduced active stiffness of muscle fibers (see Fig 2) , (2) the reduced myosin mass transfer from the thick filament backbone toward the actin filament during muscle activation (see Fig 3) , and (3) the impaired contractile force of individual myofibrils (see Fig 4) . Note that due to the limited biopsy size, these data are based on 6 to 19 fiber preparations per biopsy, a number that precludes firm, quantitative conclusions. This is the first study to determine the contractility of myofibrils from nemaline myopathy patients. It is important to note that if structural damage is present in the myofibrils, they break during the experiment and are excluded from the study. Thus, contribution of ultrastructural damage to the reduced force of myofibrils is highly unlikely (in contrast to the muscle fiber preparations, in which ultrastructural damage contributes to impaired contractile force). Importantly, the reduced force of NEM3 fibers is not per se caused by shortened thin filaments. For example, P5 has reduced active stiffness of muscle fibers (see Table 1 ), reduced myosin mass transfer during activation Fig 3C, and reduced myofibril force (see Fig 4C) , but normal thin filament length as shown by super-resolution microscopy experiments (see Fig 5A) . Thus, in addition to atrophy and ultrastructural damage in muscle fibers, impaired contractility of sarcomeres contributes to muscle weakness in NEM3.
Importantly, the extent to which these factors contribute to weakness depends on the mutation involved. For instance, fibers of P3 had low active tension, whereas the tension generated by myofibrils was relatively high. This suggests that ultrastructural damage in muscle fibers is an important contributor to weakness in P3. Conversely, P10 displayed low fiber tension and myofibril tension, suggesting that impaired sarcomere function significantly contributes to muscle weakness in this patient. Consequently, patients with contractile deficits, such as P10, are more likely to benefit from therapy aimed at improving sarcomere contractility than patients, such as P3, whose muscle weakness was mainly caused by structural damage. This information is crucial for patient stratification in future clinical trials.
Is the Shift toward a Higher Proportion of Type 1 Fibers a Protective Mechanism?
The majority of biopsies were obtained from the vastus lateralis muscle, a muscle that in healthy humans consists of approximately 45% type 1 fibers and 55% type 2 fibers. 49 It is well established that patients with nemaline myopathy can display a predominance of type 1 fibers, a phenomenon that we also observed in the current study (see Table 2 ; from 9 of 14 NEM3 patients, we isolated mainly/only type 1 fibers). Interestingly, Figure 2C illustrates that from the 5 biopsies with lowest tension generation, 4 had a mix of type 1 and type 2 fibers. Whereas maximal tension in NEM3 patients was decreased by 66% when all fiber types were compared together, this reduction was 49% when only type 1 fibers (bundles) were compared. Thus, we postulate that a shift toward a higher proportion of type 1 fibers constitutes a protective mechanism to prevent a dramatic loss of force-generating capacity of the overall muscle. In line with this postulation, we reported in previous studies on a nebulindeficient mouse model a similar shift toward type 1 fibers. Importantly, these type 1 fibers had a relatively preserved contractile force. 50 The patients (see Fig 2H) . A mutation/patient-specific effect on Ca 21 sensitivity of force has previously been reported for myopathy-associated mutations in ACTA1, 25, 26 TPM2, and TPM3. 38, 51, 52 When assessing the location of the mutated residues within the actin molecule, we found that 3 of 4 mutations causing a decreased calcium sensitivity were located in subdomain 4 (see Fig 1 for  details) . This cluster is not associated with a particular area of known function, and given the low number of mutations it is difficult to determine whether a true association between Ca 21 sensitivity and mutations in this domain exists. Previous studies reported that each actin mutation causes a distinct molecular and histological phenotype, which poorly correlates with the genotype (reviewed in Feng and Marston
53
. That we are unable to predict the functional effect of each mutation is likely due to an incomplete understanding of the regulation of actin. Most likely each mutation has a distinct effect on the molecular structure of actin, leading to effects that perhaps change the conformation of the thin filament to favor its ON or OFF state so that different amounts of Ca 21 are required for force generation. Hopefully, the growing knowledge of actin mutations and their effect on thin filament function, which this study contributes to, will improve our ability to predict genotype-phenotype correlations in the future.
Study Limitations
First, statistical testing was performed on the NEM3 patients as a group. As each individual NEM3 patient harbored a different mutation in ACTA1, which might differentially affect contractility, we considered a single patient to be different from the control subjects if the average of the single patient was >2 standard deviations (SDs) lower/higher than the average of the controls. This range (2 3 SD) is indicated in Figures 2C and H . Second, it is unclear whether the muscle tissue in a biopsy specimen is representative of the muscle as whole. Similarly, it is unknown whether fibers isolated from the biopsy represent the quality of all fibers in that biopsy. For instance, in the present study we observed that the contractile force of fibers isolated from P14 depended on the location in the biopsy from which they were obtained; some fibers were of normal size and generated maximal tensions that were nearly comparable to those of control fibers, whereas fibers isolated from another location were very thin and had very low tensions (maximal active tension of the single fibers was 102.5 6 36.9 vs 158.5 6 17.1mN/mm 2 , slow twitch vs fast twitch, respectively [see Table 2 ; n 5 15 fibers]; maximal active tension of the bundles was 6.1 6 1.3mN/mm 2 [bundles contained a mix of type 1 and type 2 fibers; n 5 7 bundles]). Considering the mild clinical phenotype of this patient (see Table 1 ), we assume that the high tensions of normal-appearing fibers better represent the overall quality of the muscle in this patient. Although we observed these discrepant results only in the biopsy of P14, this finding indicates that large variation in fiber quality might be present even within a single biopsy and that caution is warranted when interpreting data from biopsy specimens.
In conclusion, this study demonstrates that sarcomere dysfunction contributes to muscle weakness in NEM3 patients. To date, there is no cure for NM, or NEM3 in particular. Each mutation in ACTA1 results in a particular molecular abnormality, which should be taken into account when considering treatment strategies for NEM3 patients. Recently, we and others 23, 54 have
shown that agents that augment the force response to Ca 21 (eg, levosimendan, and tirasemtiv and its analogues) might benefit patients with muscle weakness, and especially those with reduced Ca 21 sensitivity of force generation. Furthermore, interventions aimed at targeting myosin have recently been explored. Intramuscular injections of recombinant adeno-associated viral vectors harboring a myosin transgene improved force production in an NEM3 mouse model. 55 The recent advances made in the development of therapeutic strategies for NEM3 together with a detailed mechanistic understanding of weakness in NM will one day result in development of clinically effective therapies to improve the quality of life of NM patients.
